Mutations and addiction to EGFR: The Achilles 'heal' of lung cancers?

Trends in Molecular Medicine

Volumn 10, Issue 10, 2004, Pages 481-486

  Gazdar, Adi F ^a,b   Shigematsu, Hisayuki ^a   Herz, Joachim ^b   Minna, John D ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; ENZYME INHIBITOR; EPIDERMAL GROWTH FACTOR; ERLOTINIB; GEFITINIB; GENE PRODUCT; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE; QUINAZOLINE;

ADENOCARCINOMA; CANCER CELL; DNA FLANKING REGION; GENDER; GENE AMPLIFICATION; GENE FUNCTION; GENE INTERACTION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; MULTIGENE FAMILY; ONCOGENE; PATHOGENESIS; PHENOTYPE; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; REVIEW; SMOKING;

EID: 4644274700     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2004.08.008     Document Type: Article

References (34)

1. J.G. Paez EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500
2. T.J. Lynch Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N. Engl. J. Med. 350 2004 2129 2139
3. J. Marx Medicine. Why a new cancer drug works well, in some patients Science 304 2004 658 659
4. I.B. Weinstein Cancer. Addiction to oncogenes - the Achilles heal of cancer Science 297 2002 63 64
5. G.M. Rubin Comparative genomics of the eukaryotes Science 287 2000 2204 2215
6. M. Huse, and J. Kuriyan The conformational plasticity of protein kinases Cell 109 2002 275 282
7. D.R. Robinson The protein tyrosine kinase family of the human genome Oncogene 19 2000 5548 5557
8. A. Gschwind The discovery of receptor tyrosine kinases: targets for cancer therapy Nat. Rev. Cancer 4 2004 361 370
9. J. Mendelsohn Antibody-mediated EGF receptor blockade as an anticancer therapy: from the laboratory to the clinic Cancer Immunol. Immunother. 52 2003 342 346
10. J. Mendelsohn, and J. Baselga Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer J. Clin. Oncol. 21 2003 2787 2799
11. R.N. Jorissen Epidermal growth factor receptor: mechanisms of activation and signalling Exp. Cell Res. 284 2003 31 53
12. T. Holbro The ErbB receptors and their role in cancer progression Exp. Cell Res. 284 2003 99 110
13. C.J. Barnes, and R. Kumar Epidermal growth factor receptor family tyrosine kinases as signal integrators and therapeutic targets Cancer Metastasis Rev. 22 2003 301 307
14. R.W. Wong Transgenic and knock-out mice for deciphering the roles of EGFR ligands Cell. Mol. Life Sci. 60 2003 113 118
15. F.R. Hirsch HER2/neu expression in malignant lung tumors Semin. Oncol. 29 2002 51 58
16. S.C. Robertson RTK mutations and human syndromeswhen good receptors turn bad Trends Genet. 16 2000 265 271
17. L. Frederick Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas Cancer Res. 60 2000 1383 1387
18. J.N. Rich Phase II trial of gefitinib in recurrent glioblastoma J. Clin. Oncol. 22 2004 133 142
19. G. Blackledge, and S. Averbuch Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors Br. J. Cancer 90 2004 566 572
20. M. Fukuoka Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer J. Clin. Oncol. 21 2003 2237 2246
21. F.E. Domann Epigenetic silencing of maspin gene expression in human breast cancers Int. J. Cancer 85 2000 805 810
22. P.A. Janne Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, 'Iressa') on an expanded access study Lung Cancer 44 2004 221 230
23. R. Sordella Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways Science 305 2004 1163 1167
24. R.J. Slebos Relationship between K-ras oncogene activation and smoking in adenocarcinoma of the human lung J. Natl. Cancer Inst. 83 1991 1024 1027
25. Y. Fukuyama K-ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer Br. J. Cancer 75 1997 1125 1130
26. J.D. Minna Cancer. A bull's eye for targeted lung cancer therapy Science 304 2004 1458 1461
27. S. Toyooka Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancer Int. J. Cancer 103 2003 153 160
28. S. Toyooka The TP53 gene, tobacco exposure, and lung cancer Hum. Mutat. 21 2003 229 239
29. K.H. Vahakangas p53 and K-ras mutations in lung cancers from former and never-smoking women Cancer Res. 61 2001 4350 4356
30. C. Metayer Cooking oil fumes and risk of lung cancer in women in rural Gansu, China Lung Cancer 35 2002 111 117
31. N. Tidow Distinct amplification of an untranslated regulatory sequence in the egfr gene contributes to early steps in breast cancer development Cancer Res. 63 2003 1172 1178
32. W. Liu Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism Clin. Cancer Res. 9 2003 1009 1012
33. H. Buerger Allelic length of a CA dinucleotide repeat in the egfr gene correlates with the frequency of amplifications of this sequence - first results of an inter-ethnic breast cancer study J. Pathol. 203 2004 545 550
34. K.R. Fitch Genetics of dark skin in mice Genes Dev. 17 2003 214 228